Maharashtra has made a significant breakthrough in the fight against tuberculosis (TB) among people living with HIV (PLHIV). The state has introduced a new drug regimen called 1HP, which reduces the treatment duration for TB prevention from six months to just 28 days. This is a game-changer, as TB remains the leading cause of death among PLHIV.
The New 1HP Regimen:
TB and HIV: A Deadly Combination:
People with compromised immune systems, such as PLHIV, diabetics, and the malnourished, are at higher risk of TB infection. TB commonly affects the lungs but can also infect other organs like the spine, brain, or kidneys.
Early Detection and Treatment:
The government has implemented a single-window facility for PLHIV to access both HIV and TB treatment. All PLHIV visiting Anti-Retroviral Therapy (ART) centers and Integrated Counselling and Testing Centres (ICTCs) with symptoms like cough, fever, night sweat, and weight loss are tested for TB.
Free Treatment and Facilities:
The facilities for TB prevention and treatment are provided free of cost to patients. This includes testing, treatment, and counseling services.
Global Efforts to Combat TB and HIV:
The World Health Organization (WHO) has launched updated guidance on HIV-associated TB, providing comprehensive recommendations for TB/HIV prevention and treatment. The WHO aims to reduce TB deaths among PLHIV by 80% by 2025.
Maharashtra's introduction of the 1HP regimen is a significant step towards achieving this goal. With early detection, treatment, and increased adherence, PLHIV can prevent morbidity and mortality due to TB infection.
(Input from various sources)
(Rehash/Vaishnavi Dalvi/MSM)
